MARKET

NVCN

NVCN

Neovasc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8223
+0.0134
+1.66%
After Hours: 0.8340 +0.0117 +1.42% 17:51 05/11 EDT
OPEN
0.7900
PREV CLOSE
0.8089
HIGH
0.8329
LOW
0.7720
VOLUME
866.95K
TURNOVER
--
52 WEEK HIGH
3.380
52 WEEK LOW
0.6800
MARKET CAP
23.75M
P/E (TTM)
-0.4776
1D
5D
1M
3M
1Y
5Y
MedTech Round Up: Update On Products By Conformis, Medtronic, Orthofix, Neovasc
The FDA has given 510(k) clearance for Conformis Inc's (NASDAQ: 
Benzinga · 1d ago
BRIEF-Neovasc Announces First Patient Enrollment In Cosima Trial
reuters.com · 1d ago
Neovasc Announces First Patient Enrollment in COSIMA Trial
via NewMediaWire �?' Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that the first patient has been enrolled in the COronary SInus Reducer for the Treatment of Refractory Microvascular Angina ("COS...
GlobeNewswire · 1d ago
H.C. Wainwright Thinks Neovasc’s Stock is Going to Recover
In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Neovasc (NVCN), with a price target of $5.00. The company's
SmarterAnalyst · 4d ago
DJ Neovasc's CEO Fred Colen on Q1 2021 Results -- Earnings Call Transcript >NVCN
Dow Jones · 5d ago
Neovasc (NVCN) Reports Q1 Loss, Lags Revenue Estimates
Neovasc (NVCN) delivered earnings and revenue surprises of 60.00% and -24.67%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 5d ago
Neovasc Q1 EPS $(0.04) Beats $(0.05) Estimate
Neovasc (NASDAQ:NVCN) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. This is a 89.47 percent increase over losses of $(0.38) per share from the same
Benzinga · 5d ago
Neovasc EPS beats by $0.05, misses on revenue
Neovasc (NVCN): Q1 GAAP EPS of -$0.04 beats by $0.05.Revenue of $0.45M (-15.1% Y/Y) misses by $0.15M.Shares -1%.Press Release
Seekingalpha · 5d ago
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NVCN. Analyze the recent business situations of Neovasc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NVCN stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 34
Institutional Holdings: 1.80M
% Owned: 6.24%
Shares Outstanding: 28.88M
TypeInstitutionsShares
Increased
5
78.49K
New
5
361.70K
Decreased
2
150.10K
Sold Out
6
2.48M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-0.23%
Healthcare Equipment & Supplies
-0.50%
Key Executives
Chairman/Independent Director
Steven Rubin
President/Chief Executive Officer
Fred Colen
Chief Financial Officer/Secretary/IR Contact Officer
Christopher Clark
Chief Operating Officer
Bill Little
Vice President
Vicki Bebeau
Vice President
Aaron Chalekian
Other
John Panton
Director
Alexei Marko
Director
Norman Radow
Independent Director
Paul Geyer
Independent Director
Douglas Janzen
No Data
About NVCN
Neovasc Inc. (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company's segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products. The Tiara is in preclinical/early clinical stage development to provide a minimally invasive transcatheter device for patients experiencing mitral regurgitation (MR) as a result of mitral heart valve disease. The Reducer is an hourglass-shaped, balloon-expandable, stainless steel, bare metal device, which is implanted in the coronary sinus, creating a restriction in venous outflow from the myocardium (the muscular layer of the heart wall). Neovasc produces Peripatch, a biological tissue product that is manufactured from pericardium.

Webull offers kinds of Neovasc Inc stock information, including NASDAQ:NVCN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVCN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVCN stock methods without spending real money on the virtual paper trading platform.